How to optimize the treatment of early stage Parkinson’s disease

Stocchi, Fabrizio; Vacca, Laura; Radicati, Fabiana Giada

doi:10.1186/2047-9158-4-4

Cited by 24 publications

(22 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LiMnPO 4 nanoparticles are found to be well blended between the wrinkles of the MWCNTs, which is clearly evidenced by TEM analysis. Moreover, the retaining of single crystallinity of the LiMnPO 4…”

Section: Discussionmentioning

confidence: 99%

“…3 Therefore, accurate and real-time detection of DA is highly crucial in clinical diagnostics. 4 There are several types of analytical techniques available for the detection of DA including highperformance liquid chromatography (HPLC), 5 spectrometry, 6 calorimetry, and electrophoresis. 7 However, the above-mentioned techniques have some limitations, particularly high-cost, being time-consuming and the usage of environmentally hazardous solvents.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Carbon supported olivine type phosphate framework: a promising electrocatalyst for sensitive detection of dopamine

Nehru

Chen

2018

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Carbon supported olivine type phosphate framework: a promising electrocatalyst for sensitive detection of dopamine

Nehru

Chen

2018

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…The most common combination was L-dopa and non-ergot DAs, reflecting adherence to the 2011 guidelines [7]. Combination therapy is considered equally effective to monotherapy, but it minimizes the risks of side effects by reducing the dose of each drug [30].…”

Section: Plos Onementioning

confidence: 99%

Adherence to treatment guideline recommendations for Parkinson’s disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016

et al. 2020

View full text Add to dashboard Cite

Background Adherence to the 2011 Japanese guidelines for treatment of Parkinson's disease (PD) in real-life practice is unknown. Methods In this retrospective longitudinal observational study, we examined patterns and trends in anti-PD drug prescriptions in 20,936 patients (�30 years of age with newly diagnosed PD [International Classification of Diseases-Tenth code G20 or PD Hoehn and Yahr scale 1-5] and one or more prescriptions) using nationwide registry data between 2008 and 2016. Data are presented as descriptive statistics. Results Half (49.6%) of the patients received levodopa (L-dopa) monotherapy, followed by nonergot dopamine agonists (DA) prescribed as monotherapy (8.3%) or with L-dopa (8.1%). Consistent with the guidelines, 75% of patients were prescribed within 13 days of initial diagnosis; L-dopa monotherapy was the most prescribed drug in patients �70 years of age, whereas non-ergot DA monotherapy was more likely to be prescribed than L-dopa in patients between 30 and 50 years of age. Inconsistent with the guidelines, L-dopa monotherapy was the most prescribed drug in patients between 51 and 69 years of age. Over the course of 4 years of treatment, the prescription rate of L-dopa monotherapy and non-ergot DA monotherapy decreased by 63.7% and 44.1%, respectively, whereas that of L-dopa and non-ergot DA combination therapy increased by 103.7%. Combination therapy with L-dopa, non-ergot DA, and monoamine oxidase-B inhibitors was gradually increased at a later stage.

show abstract

“…Clinically, the commonly used medications to treat motor symptoms in PD patients are levodopa, dopamine agonists and MAO-B inhibitors depending on the disease stage [ 39 , 40 ]. Selegiline, which is one of MAO-B inhibitors, has especially been used for the treatment of early-stage PD [ 41 , 42 , 43 ].…”

Section: Discussionmentioning

confidence: 99%

In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson’s Disease

Choi

Park

Kim

et al. 2016

IJMS

View full text Add to dashboard Cite

Monoamine oxidase (MAO) catalyzes the oxidative deamination of monoamines including dopamine (DA). MAO expression is elevated in Parkinson’s disease (PD). An increase in MAO activity is closely related to age, and this may induce neuronal degeneration in the brain due to oxidative stress. MAO (and particularly monoamine oxidase B (MAO-B)) participates in the generation of reactive oxygen species (ROS), such as hydrogen peroxide that are toxic to dopaminergic cells and their surroundings. Although the polyphenol-rich aqueous walnut extract (JSE; an extract of Juglandis Semen) has been shown to have various beneficial bioactivities, no study has been dedicated to see if JSE is capable to protect dopaminergic neurons against neurotoxic insults in models of PD. In the present study we investigated the neuroprotective potential of JSE against 1-methyl-4-phenylpyridinium (MPP+)- or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicities in primary mesencephalic cells and in a mouse model of PD. Here we show that JSE treatment suppressed ROS and nitric oxide productions triggered by MPP+ in primary mesencephalic cells. JSE also inhibited depletion of striatal DA and its metabolites in vivo that resulted in significant improvement in PD-like movement impairment. Altogether our results indicate that JSE has neuroprotective effects in PD models and may have potential for the prevention or treatment of PD.

show abstract

How to optimize the treatment of early stage Parkinson’s disease

Cited by 24 publications

References 78 publications

Carbon supported olivine type phosphate framework: a promising electrocatalyst for sensitive detection of dopamine

Carbon supported olivine type phosphate framework: a promising electrocatalyst for sensitive detection of dopamine

Adherence to treatment guideline recommendations for Parkinson’s disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016

In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson’s Disease

Contact Info

Product

Resources

About